Organovo to Present at 2019 Cell & Gene Meeting on the Mediterranean
17 April 2019 - 10:05PM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology
company pioneering the development of 3D bioprinted tissues aimed
at treating a range of serious adult and pediatric liver diseases,
today announced that Chief Medical Officer, Dr. Steven G. Hughes,
is scheduled to speak at the inaugural Cell & Gene Meeting on
the Mediterranean to be held April 23-25 in Barcelona, Spain.
This event, modeled after The Alliance for Regenerative
Medicine’s (“ARM”) highly successful Cell & Gene Meeting on the
Mesa held annually in La Jolla, California, is expected to attract
more than 250 attendees, including senior executives from leading
cell therapy, gene therapy, and tissue engineering companies
worldwide, large pharma and biotech representatives, institutional
investors, academic research institutions, patient foundations,
disease philanthropies, and members of the life science media
community.
The following are specific details regarding Organovo’s
presentation at the conference:
Event: |
|
2019 Cell & Gene Meeting on the
Mediterranean |
|
|
|
Date: |
|
April 24, 2019 |
|
|
|
Time: |
|
10:00 a.m. Central European Summer Time
(CEST) |
|
|
|
Location: |
|
Hotel Arts Barcelona, Marina 19-21, 08005
Barcelona, Spain |
A live video webcast of all company presentations will be
available at http://www.meetingonthemed.com/webcast and will also
be published on the conference website shortly after the event.
About Organovo Holdings, Inc.Organovo is a
biotech platform company that has developed a leadership position
with its revolutionary ability to 3D bioprint tissues with human
functionality. The Company is pursuing multiple IND-track programs
to develop its NovoTissues® to address a number of serious unmet
medical needs in adult and pediatric populations, initially
focusing on liver disease. Organovo’s first IND-track program for
Alpha-1-antitrypsin deficiency recently received orphan drug
designation from the FDA, and the Company expects to file its first
IND in 2020. In order to support its plan to initiate multiple
IND-track programs, the Company is providing access to its ExVive™
in vitro tissue disease modeling platform to facilitate high value
drug discovery and development collaborations. Organovo’s
wholly-owned subsidiary, Samsara Sciences, provides the Company and
its clients with high quality human liver and kidney cells for
research applications. Organovo is changing the shape of life
science research and transforming medical care. Learn more at
www.organovo.com.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. Forward-looking statements include, but are not
limited to, statements regarding the potential benefits and
therapeutic uses of the Company’s therapeutic liver tissue,
including the benefits of an orphan designation; the Company’s
expectations regarding the FDA regulatory pathway and anticipated
timelines for its regulatory filings; the Company’s ability to
successfully complete additional preclinical studies; the Company’s
ability to meet market demand; and customer demand for and
acceptance of its disease modeling and other in vitro tissue
platforms. The factors that could cause the Company's actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
possibility that the final results of the Company's preclinical
studies may be different from the Company's studies or interim
preclinical data results and may not support further clinical
development of its therapeutic tissues; the Company may not
successfully complete the required preclinical and clinical trials
required to obtain regulatory approval for its therapeutic tissues
on a timely basis or at all; the Company may not be able to obtain
sufficient raw materials to meet market demand for its therapeutic
products; risks that competitive products may adversely impact the
market opportunity for the Company’s therapeutic tissue candidates;
the Company's ability to develop, market and sell products and
services based on its technology; the expected benefits and
efficacy of the Company's products, services and technology; the
Company’s ability to execute framework agreements involving
multi-year commitments and routine use on a timely basis, or at
all; the Company’s ability to successfully complete studies and
provide the technical information required to support market
acceptance of its products, services and technology, on a timely
basis or at all; the Company’s ability to raise sufficient funds to
support its business plan and ongoing operations; the Company's
business, research, product development, regulatory approval,
marketing and distribution plans and strategies, including its use
of third party distributors; the Company’s ability to recognize
deferred revenue; and the Company’s ability to meet its fiscal-year
2019 goals and outlook. These and other factors are identified and
described in more detail in the Company's filings with the SEC,
including its Annual Report on Form 10-K filed with the SEC on May
31, 2018. You should not place undue reliance on these
forward-looking statements, which speak only as of the date that
they were made. These cautionary statements should be considered
with any written or oral forward-looking statements that the
Company may issue in the future. Except as required by applicable
law, including the securities laws of the United States, the
Company does not intend to update any of the forward-looking
statements to conform these statements to reflect actual results,
later events or circumstances or to reflect the occurrence of
unanticipated events.
Investor & Press Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Oct 2023 to Oct 2024